The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine.

ABSTRACT:

Background

Decitabine has been widely used to treat acute myeloid leukemia (AML); however as AML is a heterogeneous disease, not all patients benefit from decitabine. This study aimed to identify markers for predicting the response to decitabine.

Methods

An intersection of in vitro experiments and bioinformatics was performed using a combination of epigenetic and transcriptomic analysis. A tumor-suppressor gene associated with methylation and the response to decitabine was screened. Then the sensitivity and specificity of this marker in predicting the response to decitabine was confirmed in 54 samples from newly diagnosed AML patients treated with decitabine plus IA regimen in a clinical trial (ChiCTR2000037928).

Results

In vitro experiments showed that decitabine cau

SUBMITTER: Li Y 

PROVIDER: S-EPMC10802042 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature